Cite
HARVARD Citation
Massari, F. et al. (2016). Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. Critical reviews in oncology/hematology. pp. 254-263. [Online].